Lyra Therapeutics Inc. has announced that it received a Deficiency Letter from The Nasdaq Stock Market LLC on August 20, 2025, indicating that the company's stockholders' equity, as reported in its quarterly report for the period ending June 30, 2025, does not meet the continued listing requirement under Nasdaq Listing Rule 5550(b)(1). The rule mandates a stockholders' equity of at least $2.5 million, while Lyra's equity stands at approximately $1.6 million. This notification does not immediately affect the trading of Lyra's common stock, which will continue to trade under the symbol "LYRA." Lyra has until October 4, 2025, to submit a plan to Nasdaq to regain compliance. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days for compliance. There is no assurance the plan will be accepted or that compliance will be achieved within the allotted time frame.